{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:59:41Z","timestamp":1786982381599,"version":"build-2736575974"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T00:00:00Z","timestamp":1750204800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s12325-025-03254-z","type":"journal-article","created":{"date-parts":[[2025,6,18]],"date-time":"2025-06-18T04:33:26Z","timestamp":1750221206000},"page":"3960-3977","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Renin-Angiotensin-Aldosterone System Inhibitor Dosing After Initiation of Outpatient Sodium Zirconium Cyclosilicate Therapy: The GALVANIZE RAASi Real-World Evidence Study"],"prefix":"10.1007","volume":"42","author":[{"given":"Abiy","family":"Agiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Greatsinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin E.","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manasvi","family":"Sundar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Colman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,18]]},"reference":[{"issue":"6","key":"3254_CR1","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1080\/03007995.2018.1433141","volume":"34","author":"KA Betts","year":"2018","unstructured":"Betts KA, Woolley JM, Mu F, McDonald E, Tang W, Wu EQ. The prevalence of hyperkalemia in the United States. Curr Med Res Opin. 2018;34(6):971\u20138.","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 3","key":"3254_CR2","doi-asserted-by":"publisher","first-page":"iii36","DOI":"10.1093\/ndt\/gfz225","volume":"34","author":"AY Wang","year":"2019","unstructured":"Wang AY. Optimally managing hyperkalemia in patients with cardiorenal syndrome. Nephrol Dial Transplant. 2019;34(Suppl 3):iii36\u201344.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"3254_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1097\/CRD.0000000000000286","volume":"28","author":"J Bhinder","year":"2020","unstructured":"Bhinder J, Patibandla S, Gupta CA, Levine A, Gass AL, Lanier GM. Mineralocorticoid receptor antagonist use in heart failure with reduced ejection fraction and end-stage renal disease patients on dialysis: a literature review. Cardiol Rev. 2020;28(3):107\u201315.","journal-title":"Cardiol Rev"},{"issue":"1","key":"3254_CR4","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1161\/CIRCHEARTFAILURE.113.000709","volume":"7","author":"LA Allen","year":"2014","unstructured":"Allen LA, Shetterly SM, Peterson PN, Gurwitz JH, Smith DH, Brand DW, et al. Guideline concordance of testing for hyperkalemia and kidney dysfunction during initiation of mineralocorticoid receptor antagonist therapy in patients with heart failure. Circ Heart Fail. 2014;7(1):43\u201350.","journal-title":"Circ Heart Fail"},{"issue":"1","key":"3254_CR5","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10557-017-6767-5","volume":"32","author":"J Tamargo","year":"2018","unstructured":"Tamargo J, Caballero R, Delpon E. New therapeutic approaches for the treatment of hyperkalemia in patients treated with renin-angiotensin-aldosterone system inhibitors. Cardiovasc Drugs Ther. 2018;32(1):99\u2013119.","journal-title":"Cardiovasc Drugs Ther"},{"issue":"6","key":"3254_CR6","doi-asserted-by":"publisher","first-page":"798","DOI":"10.2215\/CJN.12651018","volume":"14","author":"BS Spinowitz","year":"2019","unstructured":"Spinowitz BS, Fishbane S, Pergola PE, Roger SD, Lerma EV, Butler J, et al. Sodium zirconium cyclosilicate among individuals with hyperkalemia: a 12-month phase 3 study. Clin J Am Soc Nephrol. 2019;14(6):798\u2013809.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"3254_CR7","doi-asserted-by":"publisher","first-page":"2886","DOI":"10.1007\/s12325-023-02518-w","volume":"40","author":"A Agiro","year":"2023","unstructured":"Agiro A, An A, Cook EE, Mu F, Chen J, Desai P, et al. Real-world modifications of renin-angiotensin-aldosterone system inhibitors in patients with hyperkalemia initiating sodium zirconium cyclosilicate therapy: the OPTIMIZE I study. Adv Ther. 2023;40(6):2886\u2013901.","journal-title":"Adv Ther"},{"issue":"6","key":"3254_CR8","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jacc.2020.11.022","volume":"77","author":"TM Maddox","year":"2021","unstructured":"Writing Committee, Maddox TM, Januzzi JL Jr, Allen LA, Breathett K, Butler J, et al. 2021 update to the 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2021;77(6):772\u2013810.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"3254_CR9","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1016\/j.jacc.2017.04.025","volume":"70","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: A report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. J Am Coll Cardiol. 2017;70(6):776\u2013803.","journal-title":"J Am Coll Cardiol"},{"key":"3254_CR10","unstructured":"Tekturna\u00ae (aliskiren) tablets prescribing information. East Hanover: Novartis; 2012."},{"issue":"12","key":"3254_CR11","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1007\/s40265-015-0435-5","volume":"75","author":"J Fongemie","year":"2015","unstructured":"Fongemie J, Felix-Getzik E. A review of nebivolol pharmacology and clinical evidence. Drugs. 2015;75(12):1349\u201371.","journal-title":"Drugs"},{"issue":"4","key":"3254_CR12","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.jash.2008.01.004","volume":"2","author":"M Destro","year":"2008","unstructured":"Destro M, Luckow A, Samson M, Kandra A, Brunel P. Efficacy and safety of amlodipine\/valsartan compared with amlodipine monotherapy in patients with stage 2 hypertension: a randomized, double-blind, multicenter study: the EX-EFFeCTS Study. J Am Soc Hypertens. 2008;2(4):294\u2013302.","journal-title":"J Am Soc Hypertens"},{"key":"3254_CR13","volume-title":"Angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (ARBs), and direct renin inhibitors for treating essential hypertension: An update","author":"GD Sanders","year":"2011","unstructured":"Sanders GD, Coeytaux R, Dolor RJ, Hasselblad V, Patel UD, Powers B, et al. Angiotensin-converting enzyme inhibitors (ACEIs), angiotensin II receptor antagonists (ARBs), and direct renin inhibitors for treating essential hypertension: An update. Rockville: Agency for Healthcare Research and Quality; 2011."},{"issue":"18","key":"3254_CR14","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","volume":"273","author":"R Garg","year":"1995","unstructured":"Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273(18):1450\u20136.","journal-title":"JAMA"},{"issue":"18","key":"3254_CR15","first-page":"e895","volume":"145","author":"PA Heidenreich","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, et al. 2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022;145(18):e895\u20131032.","journal-title":"Circulation"},{"issue":"3S","key":"3254_CR16","first-page":"S1","volume":"99","author":"Kidney Disease: Improving Global Outcomes Blood Pressure Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes Blood Pressure Work Group. KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3S):S1\u201387.","journal-title":"Kidney Int"},{"issue":"11 Suppl","key":"3254_CR17","first-page":"S212","volume":"21","author":"M Epstein","year":"2015","unstructured":"Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(11 Suppl):S212\u201320.","journal-title":"Am J Manag Care"},{"issue":"8","key":"3254_CR18","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1002\/ejhf.1793","volume":"22","author":"P Rossignol","year":"2020","unstructured":"Rossignol P, Lainscak M, Crespo-Leiro MG, Laroche C, Piepoli MF, Filippatos G, et al. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. Eur J Heart Fail. 2020;22(8):1378\u201389.","journal-title":"Eur J Heart Fail"},{"issue":"8","key":"3254_CR19","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.1199","volume":"20","author":"M Trevisan","year":"2018","unstructured":"Trevisan M, de Deco P, Xu H, Evans M, Lindholm B, Bellocco R, et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail. 2018;20(8):1217\u201326.","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"3254_CR20","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1186\/s12916-020-01659-x","volume":"18","author":"P Bidulka","year":"2020","unstructured":"Bidulka P, Fu EL, Leyrat C, Kalogirou F, McAllister KSL, Kingdon EJ, et al. Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care. BMC Med. 2020;18(1):195.","journal-title":"BMC Med"},{"issue":"10","key":"3254_CR21","doi-asserted-by":"publisher","first-page":"2203","DOI":"10.1093\/ckj\/sfab029","volume":"14","author":"TJL Humphrey","year":"2021","unstructured":"Humphrey TJL, James G, Wittbrodt ET, Zarzuela D, Hiemstra TF. Adverse clinical outcomes associated with RAAS inhibitor discontinuation: analysis of over 400 000 patients from the UK Clinical Practice Research Datalink (CPRD). Clin Kidney J. 2021;14(10):2203\u201312.","journal-title":"Clin Kidney J"},{"issue":"2","key":"3254_CR22","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40620-021-01070-6","volume":"35","author":"A Santoro","year":"2022","unstructured":"Santoro A, Perrone V, Giacomini E, Sangiorgi D, Alessandrini D, Degli EL. Association between hyperkalemia, RAASi non-adherence and outcomes in chronic kidney disease. J Nephrol. 2022;35(2):463\u201372.","journal-title":"J Nephrol"},{"key":"3254_CR23","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ahj.2021.09.014","volume":"243","author":"Y Xu","year":"2022","unstructured":"Xu Y, Fu EL, Trevisan M, Jernberg T, Sjolander A, Clase CM, et al. Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes. Am Heart J. 2022;243:177\u201386.","journal-title":"Am Heart J"},{"issue":"22","key":"3254_CR24","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.012655","volume":"8","author":"C Linde","year":"2019","unstructured":"Linde C, Bakhai A, Furuland H, Evans M, McEwan P, Ayoubkhani D, et al. Real-world associations of renin-angiotensin-aldosterone system inhibitor dose, hyperkalemia, and adverse clinical outcomes in a cohort of patients with new-onset chronic kidney disease or heart failure in the United Kingdom. J Am Heart Assoc. 2019;8(22): e012655.","journal-title":"J Am Heart Assoc"},{"key":"3254_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106277","volume":"182","author":"P Rossignol","year":"2022","unstructured":"Rossignol P, Silva-Cardoso J, Kosiborod MN, Brandenburg V, Cleland JG, Hadimeri H, et al. Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal disease. Pharmacol Res. 2022;182: 106277.","journal-title":"Pharmacol Res"},{"issue":"3","key":"3254_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213192","volume":"14","author":"M Jun","year":"2019","unstructured":"Jun M, Jardine MJ, Perkovic V, Pilard Q, Billot L, Rodgers A, et al. Hyperkalemia and renin-angiotensin aldosterone system inhibitor therapy in chronic kidney disease: a general practice-based, observational study. PLoS ONE. 2019;14(3): e0213192.","journal-title":"PLoS ONE"},{"issue":"9","key":"3254_CR27","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.repc.2020.03.015","volume":"39","author":"C Fonseca","year":"2020","unstructured":"Fonseca C, Brito D, Branco P, Frazao JM, Silva-Cardoso J, Bettencourt P. Hyperkalemia and management of renin-angiotensin-aldosterone system inhibitors in chronic heart failure with reduced ejection fraction: a systematic review. Rev Port Cardiol (Engl Ed). 2020;39(9):517\u201341.","journal-title":"Rev Port Cardiol (Engl Ed)"},{"key":"3254_CR28","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.jacc.2024.11.014","volume":"85","author":"MN Kosiborod","year":"2024","unstructured":"Kosiborod MN, Cherney DZI, Desai AS, Testani JM, Verma S, Chinnakondepalli K, et al. Sodium zirconium cyclosilicate for management of hyperkalemia during spironolactone optimization in patients with heart failure. J Am Coll Cardiol. 2024;85:971\u201384.","journal-title":"J Am Coll Cardiol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03254-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03254-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03254-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T20:29:49Z","timestamp":1757190589000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03254-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,18]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["3254"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03254-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,18]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Abiy Agiro and Ellen Colman are employees of AstraZeneca. Arun Malhotra was an employee of AstraZeneca at the time this study was conducted. Fan Mu, Erin E. Cook, Ali Greatsinger, Jingyi Chen, Manasvi Sundar and Angela Zhao are employees of Analysis Group, Inc., a consulting firm that received payment from AstraZeneca to conduct this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"As the data were de-identified, no institutional review board waiver of the requirement for informed consent was required per article 45 \u00a7CFR 164.514(e). Patient data were used in accordance with the Helsinki Declaration as revised in 2013. The study team received permission from HealthVerity to access and use the study data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}